Clinical trial

Role of Mitophagy in Myeloid Cells During Coronary Atherosclerosis.

Name

NUGUYEN AOI 2022

Description

Atherosclerosis (deposition of a plaque essentially composed of lipids on the artery walls) is a frequent condition and is a leading cause of death worldwide. In addition to the long-established risk factors such as age, hypertension, diabetes or sedentary lifestyle, it has been demonstrated that immune cells can participate in the genesis of atherosclerotic plaques through metabolic and mitochondrial reprogramming. A non-invasive marker of this immune reprogramming has yet to be identified. Through the comparison of a group of atheromatous patients and a group of non-atheromatous patients, this study aims to evaluate this reprogramming phenomenon using a novel non-invasive method. This monocentric interventional study will take place at the Dijon Bourgogne University Hospital and will include 50 patients divided into 2 groups: "atheromatous coronary patients" and "non-atheromatous patients". The duration of participation in this study is 1 month. This study is based on usually performed procedures. Only blood samples will be taken on a catheter usually used during any cardiac surgery in addition to the medical care that is provided during hospitalization.

Trial arms

Trial start

2023-11-14

Estimated PCD

2025-12-01

Trial end

2025-12-01

Status

Recruiting

Treatment

Blood samples

at the beginning of the extracorporeal circulation, at the end of the extracorporeal circulation and at D1

Arms:

Atheromatous coronary patients, Non-atheratomous patients

myocardial tissue samples

use of usually harvested right auricular tissue

Arms:

Atheromatous coronary patients, Non-atheratomous patients

Data collection

pre-operative data: demographic data, severity scores, co-morbidities, treatments administered, collection of the presence and stage of arteriosclerotic disease, SYNTAX score Collection of data on the procedure Data from the clinical evaluation and daily biological examinations until D7 data from the follow-up consultation between D30 and D60: late complications, total length of stay in intensive care and hospital

Arms:

Atheromatous coronary patients, Non-atheratomous patients

Size

Primary endpoint

Mitophagy level by flow cytometry

Before the introduction of extracorporeal circulation.

Eligibility criteria

Inclusion Criteria: - Person who provides oral consent Group 1: - Patient scheduled for cardiac bypass surgery (isolated procedure) with extracorporeal circulation Group 2: * Patient scheduled for valve ou ascending aorta surgery with extracorporeal circulation * No coronary lesion * No peripheral arterial disease (limbs, carotids, aortic aneurysm) Exclusion Criteria: * Person not affiliated with national health care system * Medication that alters mitochondrial function (Chloroquine, hydroxychloroquine, rapamycin, carbamazepine, resveratrol, sildenafil) * Person under a legal protection measure (curatorship, guardianship, tutorship) * Pregnant, parturient or breastfeeding women * Major unable to express consent * Minor

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 50, 'type': 'ESTIMATED'}}

Updated at

2024-02-15

1 organization

1 indication

Organization

Centre Hospitalier Universitaire Dijon

Indication

Coronary Heart Disease